A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions

Pathology

Volumn 39, Issue 4, 2007, Pages 391-395

  Wood, Benjamin ^a,c   Junckerstorff, Reimar ^a   Sterrett, Gregory ^a   Frost, Felicity ^a   Harvey, Jennet ^a,b   Robbins, Peter ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Core biopsy; HER 2; Oestrogen receptor; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; BREAST SURGERY; CANCER GRADING; CANCER SIZE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS;

EID: 34547691212     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020701444465     Document Type: Article

References (15)

1. Goldhirsch A, Wood W, Gelber R, et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-65.
2. Tokunaga E, Oki E, Nishida K, et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 2006; 11: 199-208.
3. Australian Cancer Network. The Pathology Reporting of Breast Cancer. A Guide for Pathologists, Surgeons, Radiologists and Oncologists. North Sydney: IntraMed Educational Group, 2001. http ://www.cancer.org.au/documents/ The_Pathology_reporting _of_breast_cancer_2001.pdf (accessed Aug 2006).
4. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of the national testing guidelines. Mod Pathol 2003; 16: 173-82.
5. Burge C, Chang H, Apple S. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 2006; 15: 167-72.
6. Mann G, Fahey V, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005; 23: 5148-54.
7. Allred D, Harvey J, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
8. Osborne C, Yochmowitz M, Knight W, et al. The value of oestrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884-8.
9. Osborne C, Schiff R, Arpino G, et al. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 2005; 14: 458-65.
10. Layfield L, Gupta D, Mooney E. Assessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques and quantitation methods. Breast J 2000; 6: 189-96.
11. Rhodes A, Jasani B, Barnes D, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125-30.
12. Douglas-Jones A, Collett N, Morgan J, et al. Comparison of oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of Er in breast carcinoma. J Clin Pathol 2001; 54: 951-5.
13. Cahill R, Walsh D Landers R, et al. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Ann Surg Oncol 2006; 13: 45-51.
14. Tubbs R, Pettay J, Roche P, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent false positives do not get the message. J Clin Oncol 2001; 19: 2714-21.
15. Loring P, Cummins R, O'Grady A, et al. HER2 positivity in breast carcinoma: A comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity. Appl Immunhistochem Mol Morphol 2005; 13: 194-200.